With first-quarter results that significantly surpassed analyst expectations, investors might find themselves shaking their heads or smiling widely - depending on whether or not they bought Genentech Inc.'s stock a year ago when it was running in the mid-$30 range. (BioWorld Today)
As Indevus Pharmaceuticals Inc.'s overactive bladder product nears the market, the company laid out a U.S. commercialization plan with Zagreb, Croatia-based Pliva d.d. (BioWorld Today)
Pricing significantly below its intended range, Memory Pharmaceuticals Corp. raised $35 million in its initial public offering Monday. (BioWorld Today)
It may have been a day filled with pranks, cranks and guffaws, but there was no fooling around at Santarus Inc.'s offices in San Diego on Thursday. The company celebrated April 1 by raising $54 million in its initial public offering, pricing 6 million shares at $9 each. (BioWorld Today)
In one of the largest biotech deals this year, Amgen Inc. caught the big fish, so to speak, by reeling in Tularik Inc. with a $1.3 billion takeover bid. (BioWorld Today)
